Citations

Mayo Clinic

Showing 10 of 108537 citations.

Evaluating User Experience and DNA Yield from Self-Collection Devices
Blommel, Joseph H. , Roforth, Matthew M., Jerde, Calvin R. , Karsten, Carley A., Bridgeman, Amber R. , Voss, Jesse S. , Ivankovic, Diana S., Kipp, Benjamin R. , Boccuto, Luigi , Sarasua, Sara M. , Murphy, Stephen J.

The Journal of Applied Laboratory Medicine | May 20, 2024 | Volume: 9 | Issue: 4 | Pages: 704-715

10.1093/jalm/jfae030 | PMID 38767175 Get It

Abstract Background The COVID-19 pandemic emphasized an urgent need for devices used in the self-collection of biospecimens in an evolving patient care system. The mailing of biospecimen self-collection kits to patients, with samples returned via mail, provides a more convenient testing regimen, but could also impart patient sampling variabilities. User compliance with device directions is central to downstream testing of collected biospecimens and clear instructions are central to this goal. Methods Here, we performed an evaluation of 10 oral DNA collection devices involving either swab or saliva self-collection and analyzed ease of use and comfort level with a device, as well as DNA recovery quantity/quality and sample stability. Results We show that while these DNA quality/quantity metrics are comparable between devices, users prefer direct saliva collection over swab-based devices. Conclusions This information is useful in guiding future experiments including their use in human RNA, microbial, or viral sample collection/recovery and their use in clinical testing.
Reply to “Performance of GPT-4 Vision on kidney pathology exam questions”
Miao, Jing , Cheungpasitporn, Wisit , Cornell, Lynn D. , Cornell, Lynn , Cheungpasitporn, Wisit , Miao, Jing , Thongprayoon, Charat

American Journal of Clinical Pathology | May 20, 2024 | Volume: 162 | Issue: 5 | Pages: 536-536

10.1093/ajcp/aqae059 | PMID 38767048 Get It

Changes in nutritional status and the development of obesity and metabolic syndrome following pediatric heart transplantation
Sill, Jordan , Lukich, S., Alejos, A., Lim, H. , Chau, P., Lowery, Ray , McCormick, Amanda D. , Peng, David M. , Yu, Stella X. , Schumacher, Kurt R. , Lim, Heang M. , Sill, J , McCormick, A , Peng, D M , Schumacher, K R , Yu, S., Lim, Heang M.

Pediatric Transplantation | May 20, 2024 | Volume: 28 | Issue: 4 | Pages: No page available

10.1111/petr.14782 | PMID 38767001 Get It

AbstractBackgroundNutritional status in pediatric patients undergoing heart transplantation (HT) is frequently a focus of clinical management and requires high resource utilization. Pre‐operative nutrition status has been shown to affect post‐operative mortality but no studies have been performed to assess how nutritional status may change and the risk of developing nutritional comorbidities long‐term in the post‐transplant period.MethodsA single‐center retrospective chart review of patients ≥2 years of age who underwent heart transplantation between 1/1/2005 and 4/30/2020 was performed. Patient data were collected at listing, time of transplant, 1‐year, and 3‐year follow‐up post‐transplant. Nutrition status was classified based on body mass index (BMI) percentile in the primary analysis. Alternative nutritional indices, namely the nutrition risk index (NRI), prognostic nutrition index (PNI), and BMI z‐score, were utilized in secondary analyses.ResultsOf the 63 patients included, the proportion of patients with overweight/obese status increased from 21% at listing to 41% at 3‐year follow‐up. No underweight patients at listing became overweight/obese at follow‐up. Of patients who were overweight/obese at listing, 88% maintained that status at 3‐year follow‐up. Overweight/obese status at listing, 1‐year, and 3‐year post‐transplantation were significantly associated with developing metabolic syndrome. In comparison to the alternative nutritional indices, BMI percentile best predicted post‐transplant metabolic syndrome.ConclusionsThe results suggest that pediatric patients who undergo heart transplantation are at risk of developing overweight/obesity and related nutritional sequelae (ie, metabolic syndrome). Improved surveillance and interventions targeted toward overweight/obese HT patients should be investigated to reduce the burden of associated comorbidities.
Treatment‐associated decline in JAK2 V617F allele burden in polycythemia vera: What does it mean?
Tefferi, Ayalew , Pardanani, Animesh , Gangat, Naseema

American Journal of Hematology | May 20, 2024 | Volume: 99 | Issue: 8 | Pages: 1459-1461

10.1002/ajh.27375 | PMID 38767433 Get It

Colorectal Sarcomatoid Carcinoma: 30-Year Experience
Souza, Dante L. S. , Kelley, Scott R.

The American Surgeon™ | May 20, 2024 | Volume: 90 | Issue: 11 | Pages: 2824-2831

10.1177/00031348241256073 | PMID 38767188 Get It

Background: Primary colorectal sarcomatoid carcinoma is a rare and aggressive malignant neoplasm that displays mixed epithelial and mesenchymal differentiation, with uncertain histogenesis. First described in 1986, there is a paucity of literature related to this condition and there are no evidence-based treatment guidelines. The aim of our study is to present our 30-year experience with primary colorectal sarcomatoid carcinoma. Methods: Retrospective single-center analysis of all patients treated for primary colorectal sarcomatoid carcinoma from 1992 to 2022. The primary outcome was response to treatment strategy and overall survival. Results: A total of six cases met eligibility criteria. Three were male (50%) with a mean age at diagnosis of 59 years (range, 49-72). Four neoplasms were located in the rectum (66%) and two in the colon. Mean tumor size at diagnosis was 4.8 cm (range, 2.8-7.0). Three patients were treated endoscopically and three underwent oncologic surgical resection. Five experienced recurrence and one expired from other comorbidities. The mean survival among those with colonic and rectal sarcomatoid carcinoma was 7 months (range, 3-11) and 39 months (range, 9-60), respectively. Discussion: Primary colorectal sarcomatoid carcinoma is a rare malignant tumor with poor prognosis. Treatment modalities have not been standardized and despite multimodal therapy, disease recurrence and/or metastasis is likely to occur. Further studies are necessary to determine optimal treatment to improve outcomes.
Clinical Features of Cutaneous Paraneoplastic Syndromes in Hodgkin Lymphoma
McCormick, Benjamin J. , Zieman, Daniel, Sluzevich, Jason C. , Moustafa, Muhamad Alhaj , Moustafa, Muhamad Alhaj , Sluzevich, Jason C

Journal of Investigative Medicine High Impact Case Reports | May 20, 2024 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/23247096241255840 | PMID 38767173 Get It

Cutaneous paraneoplastic syndromes due to Hodgkin lymphoma present with a wide spectrum of clinical manifestations from generalized pruritus to exfoliative erythroderma. We summarize the clinical findings and outcomes of 14 patients with Hodgkin lymphoma and associated cutaneous paraneoplastic syndromes treated at Mayo Clinic over the past 3 decades. Cutaneous paraneoplastic syndromes may be present at the time of lymphoma diagnosis, whereas in other patients, it may appear at the time of relapse, including patients with initial absence of cutaneous manifestations during the initial lymphoma presentation. Our results indicate that complete resolution of the paraneoplastic syndrome is associated with significantly improved overall survival. Recognition of cutaneous paraneoplastic syndromes is a crucial surrogate of relapsed malignancy and treatment requires targeting the underlying malignancy.
Impact of Glucocorticoid Dose on Complete Response, Serious Infections, and Mortality During the Initial Therapy of Lupus Nephritis: A Systematic Review and Meta‐Analysis of the Control Arms of Randomized Controlled Trials
Figueroa‐Parra, Gabriel , Cuéllar‐Gutiérrez, María C. , González‐Treviño, Mariana , Sánchez-Rodríguez, Alain , Flores‐Gouyonnet, Jaime , Meade‐Aguilar, José A. , Prokop, Larry J. , Dall’Era, Maria , Rovin, Brad H. , Houssiau, Frédéric , Tamirou, Farah, Crowson, Cynthia S. , Putman, Michael , Dall'Era, María , Rovin, Brad H , Houssiau, Frédéric , Fervenza, Fernando C , Crowson, CS , Duarte-García, Alí , Figueroa-Parra, Gabriel , Prokop, Larry , Meade-Aguilar, Jose Antonio , Gonzalez-Treviño, Mariana , Murad, M. Hassan , Fervenza, Fernando C. , Duarte‐García, Alí

Arthritis & Rheumatology | May 20, 2024 | Volume: 76 | Issue: 9 | Pages: 1408-1418

10.1002/art.42920 | PMID 38766897 Get It

ObjectiveOur objective was to evaluate the effect of glucocorticoid regimens on renal response, infections, and mortality among patients with lupus nephritis (LN).MethodsWe performed a systematic review and meta‐analysis of the control arms of randomized clinical trials (RCTs). We included RCTs of biopsy‐proven LN that used a protocolized regimen of glucocorticoids in combination with mycophenolic acid analogs or cyclophosphamide and reported the outcomes of complete response (CR), serious infections, and death. The starting dosage of glucocorticoids, tapering method, and administration of glucocorticoid pulses were abstracted. Meta‐analysis of proportions, meta‐regression, and subgroup meta‐analysis were performed at 6 and 12 months for all outcomes.ResultsFifty RCT arms (3,231 patients with LN) were included. The predicted rates of CR, serious infections, and death when starting on oral prednisone at 25 mg/day without pulses were 19.5% (95% confidence interval [CI] 7.3–31.5), 3.2% (95% CI 2.4–4.0), and 0.2% (95% CI 0.0–0.4), respectively. Starting on prednisone at 60 mg/day (without pulses) increased the rates to 34.6% (95% CI 16.9–52.3), 12.1% (95% CI 9.3–14.9), and 2.7% (95% CI 0.0–5.3), respectively. Adding glucocorticoid pulses increased the rates of CR and death but not serious infections. We observed a dose–response gradient between the initial glucocorticoid dosage and all the outcomes at six months after accounting for the administration of glucocorticoid pulses, underlying immunosuppressant, and baseline proteinuria.ConclusionA higher exposure to glucocorticoids during the initial therapy of LN was associated with better renal outcomes at the cost of increased infections and death.
A Novel Positive-Contrast Magnetic Resonance Imaging Line Marker for High-Dose-Rate (HDR) MRI-Assisted Radiosurgery (MARS)
Bruno, Teresa L., Sanders, Jeremiah , Ning, Matthew S. , Ma, Jingfei , Klopp, Ann H. , Venkatesan, Aradhana M. , Martirosyan, Karen S. , Sanders, Jeremiah W , Ning, Matthew S , Ma, Jingfei , Klopp, Ann H , Martirosyan, Karen S , Venkatesan, Aradhana M , Wang, Li , Ding, Yao , Stafford, R. Jason , Lin, Eric, Bathala, Tharakeswara K , Wang, Jihong , Frank, Steven J.

Cancers | May 20, 2024 | Volume: 16 | Issue: 10 | Pages: 1922

10.3390/cancers16101922 | PMID 38792000 Get It

Magnetic resonance imaging (MRI) can facilitate accurate organ delineation and optimal dose distributions in high-dose-rate (HDR) MRI-Assisted Radiosurgery (MARS). Its use for this purpose has been limited by the lack of positive-contrast MRI markers that can clearly delineate the lumen of the HDR applicator and precisely show the path of the HDR source on T1- and T2-weighted MRI sequences. We investigated a novel MRI positive-contrast HDR brachytherapy or interventional radiotherapy line marker, C4:S, consisting of C4 (visible on T1-weighted images) complexed with saline. Longitudinal relaxation time (T1) and transverse relaxation time (T2) for C4:S were measured on a 1.5 T MRI scanner. High-density polyethylene (HDPE) tubing filled with C4:S as an HDR brachytherapy line marker was tested for visibility on T1- and T2-weighted MRI sequences in a tissue-equivalent female ultrasound training pelvis phantom. Relaxivity measurements indicated that C4:S solution had good T1-weighted contrast (relative to oil [fat] signal intensity) and good T2-weighted contrast (relative to water signal intensity) at both room temperature (relaxivity ratio > 1; r2/r1 = 1.43) and body temperature (relaxivity ratio > 1; r2/r1 = 1.38). These measurements were verified by the positive visualization of the C4:S (C4/saline 50:50) HDPE tube HDR brachytherapy line marker on both T1- and T2-weighted MRI sequences. Orientation did not affect the relaxivity of the C4:S contrast solution. C4:S encapsulated in HDPE tubing can be visualized as a positive line marker on both T1- and T2-weighted MRI sequences. MRI-guided HDR planning may be possible with these novel line markers for HDR MARS for several types of cancer.
Precision medicine within health professions education: Defining a research agenda for emergency medicine using a foresight and strategy technique (FaST) review
Chan, Teresa M. , Thoma, Brent , Finnell, John T. , Gordon, Bradley D. , Farrell, Susan , Pusic, Martin , Cabrera, Daniel , Gisondi, Michael A. , Caretta‐Weyer, Holly , Stave, Christopher D , Caretta-Weyer, Holly A , Stave, Christopher , Ankel, Felix , Pusic, Martin V , Cabrera, Daniel , Finnell, John T. , Ankel, Felix

AEM Education and Training | May 20, 2024 | Volume: 8 | Issue: S1 | Pages: No page available

10.1002/aet2.10983 | PMID 38774830 Get It

Abstract Background Precision medicine, sometimes referred to as personalized medicine, is rapidly changing the possibilities for how people will engage health care in the near future. As technology to support precision medicine exponentially develops, there is an urgent need to proactively improve our understanding of precision medicine and pose important research questions (RQs) related to its inclusion in the education and training of future emergency physicians. Methods A seven‐step process was employed to develop a research agenda exploring the intersection of precision and emergency medicine education/training. A literature search of articles about precision medicine was conducted first, which informed the creation of future four scenarios in which trainees and practicing physicians regularly discuss and incorporate precision medicine tools into their discussions and work. Based on these futurist narratives, potential education RQs were generated by an expert panel. A total of 59 initial questions were subsequently categorized and refined to a priority list through a nominal group voting method. The top/priority questions were presented at the 2023 SAEM Consensus Conference on Precision Medicine, Austin, Texas, for further input. Results Eight high‐value education RQs were developed, reflecting a holistic view of the challenges and opportunities for precision medicine education in the knowledge, skills, and attitudes relevant to emergency medicine. These questions contend with topics such as most effective pedagogical methods; intended resulting outcomes and behaviors; the generational differences between practicing emergency physicians, educators, and future trainees; and the desires and expectations of patients. Conclusions Emergency medicine and emergency physicians must be prepared to understand precision medicine and incorporate this information into their “toolbox” of thinking, problem solving, and communication with patients and colleagues. This research agenda on how best to educate future emergency physicians in the use of personalized data to provide optimal health care is the focus of this article.
When the Third Time Is Not the Charm—Trial Outcomes in Idiopathic Pulmonary Fibrosis
Zamora, Ana, Ortega, Victor E. , Carmona, Eva M. , Zamora, Ana C., Carmona, Eva M

JAMA | May 19, 2024 | Volume: 332 | Issue: 5 | Pages: 374

10.1001/jama.2024.8776 | PMID 38762799 Get It